genOway
ALGEN | XPAR
Overview
Corporate Details
- ISIN(s):
- FR0004053510
- LEI:
- 969500HMHUPR3KYXUT19
- Country:
- France
- Address:
- 31 RUE SAINT JEAN DE DIEU, 69007 LYON
- Website:
- https://www.genoway.com
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Founded in 1999, genOway is a global biotechnology company dedicated to the development and commercialization of unique, innovative genetically modified mouse, rat and cell line models for fundamental, preclinical and clinical research. Based on its core business and leading expertise in custom-designed models, the company invests in cancer research, with a growing catalog of currently over 30 translational models for immuno-oncology and immunotherapy. genOway holds all relevant licenses on patented technologies used for its model creation, including the exclusive license under Merck’s foundational CRISPR/Cas9 patents portfolio, which enables the company to guarantee its clients FTO, freedom to operate. Headquartered in Lyon, France, genOway serves clients in 380 academic institutions and 170 life sciences companies, including 17 of the top 20 pharma.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-03-27 17:55 |
Earnings Release
Résultats annuels 2024 - genOway accélère le déploiement de son plan stratégiqu…
|
French | 223.0 KB | |
| 2025-01-20 18:00 |
Inside Information Statement
Croissance solide de +10% de l'activité en 2024 à 22,1 M EUR
|
French | 194.7 KB | |
| 2024-11-04 18:00 |
Regulatory News Service
Lutte contre l'obésité et les maladies métaboliques : les modèles humanisés de …
|
French | 130.1 KB | |
| 2024-09-23 18:00 |
Earnings Release
Résultats semestriels 2024 conformes avec les objectifs du nouveau plan stratég…
|
French | 207.7 KB | |
| 2024-07-18 18:00 |
Earnings Release
Un 1er semestre 2024 en croissance de +15%, de bon augure en pleine mise en oeu…
|
French | 176.4 KB | |
| 2024-07-04 18:00 |
Regulatory News Service
Bilan semestriel du contrat de liquidité
|
French | 355.0 KB | |
| 2024-06-25 17:55 |
Earnings Release
Solide démarrage du développement de la coentreprise genOway Shanghai en Chine
|
French | 198.0 KB | |
| 2024-03-28 18:00 |
Investor Presentation
Organisation d'une visioconférence destinée aux investisseurs individuels
|
French | 128.0 KB | |
| 2024-03-26 17:45 |
Inside Information Statement
Résultats annuels 2023 : genOway poursuit sur sa lancée avec une croissance de …
|
French | 219.5 KB | |
| 2024-02-09 11:00 |
Regulatory News Service
genOway fait son entrée au palmarès 2024 des 500 ' Champions de la croissance '
|
French | 129.5 KB | |
| 2024-01-22 08:00 |
Regulatory News Service
genOway participe à la 1ère édition du Retail Day organisée par Euroland Corpor…
|
French | 125.7 KB | |
| 2024-01-16 18:05 |
Earnings Release
genOway dévoile Route 50+, son nouveau plan stratégique visant à bâtir un leade…
|
French | 198.9 KB | |
| 2024-01-16 18:00 |
Earnings Release
genOway dépasse le seuil des 20 M EUR de chiffre d'affaires en 2023, porté par …
|
French | 176.3 KB | |
| 2023-11-22 18:00 |
Inside Information Statement
Initiation de la couverture du titre genOway par Euroland Corporate
|
French | 100.2 KB | |
| 2023-10-17 18:00 |
Regulatory News Service
genOway crée une coentreprise à Shanghai avec pour objectif de devenir le parte…
|
French | 141.9 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-17 | N/A | Other | Sell | 1,700 | 8,160.00 EUR |
| 2023-12-15 | N/A | Other | Sell | 5,000 | 22,000.00 EUR |
| 2023-11-23 | N/A | Other | Sell | 500 | 2,100.00 EUR |
| 2023-10-23 | N/A | Other | Sell | 100 | 390.00 EUR |
| 2023-09-25 | N/A | Other | Buy | 5,000 | 20,000.00 EUR |
| 2023-05-04 | N/A | Other | Buy | 60,000 | 222,000.00 EUR |
| 2023-05-02 | N/A | Other | Sell | 20,000 | 74,000.00 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ANIMALCARE GROUP PLC | United Kingdom | ANCR | |
|
Annexin Pharmaceuticals AB | Sweden | ANNX | |
|
Apontis Pharma AG | Germany | APPH | |
|
Aptahem AB | Sweden | APTA | |
|
Arctic Bioscience | Norway | ABS | |
|
ArcticZymes Technologies | Norway | AZT | |
|
argenx SE | Netherlands (Kingdom of the) | 1AE | |
|
ARIX BIOSCIENCE PLC | United Kingdom | ARIX | |
|
AroCell AB | Sweden | AROC | |
|
Arterra Bioscience | Italy | ABS |